A patient taking amlodipine 10 mg daily for hypertension develops supraventricular tachycardia. What is the appropriate starting dose of diltiazem controlled‑release when switching from amlodipine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Starting Dose of Diltiazem CD When Switching from Amlodipine for SVT

Start diltiazem CD at 120 mg once daily when switching from amlodipine 10 mg for SVT management. 1

Rationale for 120 mg Starting Dose

The 2015 ACC/AHA/HRS SVT guidelines explicitly state that for ongoing oral management of supraventricular tachycardia, diltiazem should be initiated at 120 mg daily in divided or single dose with long-acting formulations 1. This is the guideline-recommended starting dose regardless of prior calcium channel blocker exposure.

Key Considerations for This Transition

Why Not Start Higher Despite Amlodipine 10 mg Use

  • Different mechanisms: Amlodipine is a dihydropyridine with predominantly peripheral vascular effects and minimal AV nodal blocking properties 2. Diltiazem is a non-dihydropyridine with significant AV nodal effects, which is why it's effective for SVT rate control 1
  • Starting at 120 mg allows assessment of AV nodal effects before escalating, as the patient has not been exposed to a rate-controlling calcium channel blocker previously
  • The maximum dose can reach 360 mg daily if needed for adequate SVT control 1

Critical Safety Precautions

Before initiating diltiazem, ensure the patient does NOT have 1:

  • AV block greater than first degree or SA node dysfunction (without pacemaker)
  • Decompensated systolic heart failure or severe LV dysfunction
  • Hypotension (diltiazem can worsen this)
  • Wolff-Parkinson-White syndrome with atrial fibrillation/flutter

Titration Strategy

  • Start at 120 mg daily (long-acting formulation)
  • Titrate upward based on SVT control and tolerability
  • Maximum dose is 360 mg daily 1
  • Monitor for hypotension, worsening heart failure symptoms, bradycardia, and abnormal liver function 1

Drug Interaction Alert

Diltiazem is a moderate CYP3A4 inhibitor and substrate 1. Be cautious with concurrent medications metabolized by this pathway, including certain statins, immunosuppressants, and anticoagulants.

Overlap vs. Direct Switch

Do not overlap amlodipine and diltiazem due to additive hypotensive effects and the guideline caution about "drugs with SA and/or AV nodal-blocking properties" 1. Stop amlodipine when starting diltiazem, monitoring blood pressure closely during the transition since you're switching from a potent antihypertensive to a lower starting dose of another agent.

Blood Pressure Management During Transition

The patient was on amlodipine 10 mg for hypertension. Starting diltiazem at 120 mg may provide less blood pressure reduction initially compared to amlodipine 10 mg 3, 4. Monitor blood pressure closely and be prepared to uptitrate diltiazem or add additional antihypertensive therapy if blood pressure control deteriorates while achieving SVT control.

Related Questions

Is it safe to take amlodipine (calcium channel blocker) and diltiazem (calcium channel blocker) together?
Is it appropriate to switch the patient from diltiazem to amlodipine?
Which calcium channel blocker, amlodipine or diltiazem, is more effective at lowering blood pressure?
What is the equivalent dose of amlodipine for a patient taking diltiazem 240mg?
In an 81-year-old woman with hypertension who developed atrial fibrillation with rapid ventricular response and hypertensive urgency after receiving furosemide, and who is currently on a diltiazem infusion with a blood pressure of 167/78 mmHg and unremarkable labs, what further management is required?
In a 17-year-old boy with a two-year history of unilateral vision loss and a self-settled partial retinal detachment, suspected vitreous-retinal vasculitis, and no systemic features, how significant is a low-positive cytoplasmic antineutrophil cytoplasmic antibody (C-ANCA) titer (moderate ++, 1:20) with a normal erythrocyte sedimentation rate (14 mm/h) and negative antinuclear antibody (ANA)?
Should I add azithromycin (Z‑Pack) to amoxicillin for a patient with left acute otitis media and a persistent croup‑like cough?
What is the recommended treatment for a distal biceps tendon rupture?
What is the anatomy and pathophysiology of an obturator hernia?
In a postpartum woman with blood pressure controlled on nifedipine who is experiencing headaches, what is the appropriate evaluation and management?
What is the appropriate treatment for diabetic ketoacidosis (DKA) in adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.